| Joann Sampolski, APN | |
|
1907 New Rd, Northfield, NJ 08225-1545 | |
| (609) 645-8884 | |
| (609) 645-9780 |
| Full Name | Joann Sampolski |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 1907 New Rd, Northfield, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730623216 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SG0600X | Clinical Nurse Specialist - Gerontology | 26NJ00690200 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pain Specialists, Pa | 5890699888 | 7 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.
A joint research published today in Nature Communications has shown new molecular causes of brain cancer and leukemia.
› Verified 6 days ago
| Entity Name | Pain Specialists, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922161470 PECOS PAC ID: 5890699888 Enrollment ID: O20031121000248 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.
A joint research published today in Nature Communications has shown new molecular causes of brain cancer and leukemia.
› Verified 6 days ago
| Entity Name | Shore Atlantic Geriatrics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508882051 PECOS PAC ID: 7416985015 Enrollment ID: O20050913000092 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.
A joint research published today in Nature Communications has shown new molecular causes of brain cancer and leukemia.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joann Sampolski, APN 108 S Montpelier Ave, Apt 320, Atlantic City, NJ 08401-6271 Ph: (609) 320-8068 | Joann Sampolski, APN 1907 New Rd, Northfield, NJ 08225-1545 Ph: (609) 645-8884 |
News Archive
Roche announced today that the U.S. Food & Drug Administration (FDA) has approved the real-time PCR COBAS® TaqMan® HCV Test, v2.0. Clinical research organizations have depended on COBAS® TaqMan® technology to support hepatitis C pharmaceutical trials and development.
Men with localized prostate cancer treated with a newer technology, intensity modulated radiation therapy (IMRT), have more than a quarter (26 percent) fewer late bowel and rectal side effects and a statistically improved lower dose of radiation to the bladder and rectum, compared to those who undergo 3D-CRT, according to a randomized study presented at the plenary session October 3, 2011, at the 53rd Annual Meeting of the American Society for Radiation Oncology.
Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.
A joint research published today in Nature Communications has shown new molecular causes of brain cancer and leukemia.
› Verified 6 days ago